A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS)

被引：0
|
作者：
Nazha, Aziz [1 ]
Seastone, David J. [1 ]
Radivoyevitch, Tomas [1 ]
Gerds, Aaron T. [1 ]
Mukherjee, Sudipto [1 ]
Carraway, Hetty E. [1 ]
Advani, Anjali S. [1 ]
Kalaycio, Matt E. [1 ]
Rupp, Gina [1 ]
Colaluka, Kristin [1 ]
Hobson, Sean [1 ]
Maciejewski, Jaroslaw P. [1 ]
Sekeres, Mikkael A. [1 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Prognostic impact of bone marrow fibrosis in myelodysplastic syndromes (MDS)
    Baghikar, S.
    Braunstein, S.
    Reinecke, P.
    Knipp, S.
    Haas, R.
    Hildebrandt, B.
    Gattermann, N.
    Germing, U.
    Schmidt-Graef, A.
    LEUKEMIA RESEARCH, 2007, 31 : S100 - S100
  • [22] Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS)
    Cervera, J.
    Sole, F.
    Haase, D.
    Luno, E.
    Such, E.
    Nomdedeu, B.
    Costa, D.
    Bernal, T.
    Vallespi, T.
    Bueno, J.
    Pedro, C.
    Mallo, M.
    Ardanaz, M. T.
    Calasanz, M. J.
    del Canizo, C.
    Hernandez-Rivas, J. M.
    Schanz, J.
    Steidl, C.
    Hildebrandt, B.
    Carbonell, F.
    Orero, M.
    Ramos, F.
    Marco, V.
    Tormo, M.
    Gomez, V.
    Andreu, R.
    Xicoy, B.
    Amigo, M. L.
    Munoz, J. A.
    Bonanad, S.
    Arrizabalaga, B.
    Senent, M. L.
    Germing, U.
    Sanz, G. F.
    LEUKEMIA RESEARCH, 2009, 33 : S75 - S76
  • [23] A BMT model mouse for myelodysplastic syndromes (MDS) and MDS/overt leukemia
    Watanabe-Okochi, N.
    Kitaura, J.
    Harada, H.
    Ono, R.
    Inaba, T.
    Nakajima, H.
    Nosaka, T.
    Kitamura, T.
    EXPERIMENTAL HEMATOLOGY, 2006, 34 (09) : 63 - 63
  • [24] Soluble IL-2 receptors: A prognostic factor for MDS patients with myelodysplastic syndromes
    Bourantas, K
    Tsiara, S
    Mavridis, A
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1996, 15 (01) : 43 - 47
  • [25] HALP score as a novel prognostic factor for patients with myelodysplastic syndromes
    Gursoy, Vildan
    Sadri, Sevil
    Kucukelyas, Hatice Demirci
    Hunutlu, Fazil Cagri
    Pinar, Ibrahim Ethem
    Yegen, Zafer Serenli
    Alkis, Nihan
    Ersal, Tuba
    Ali, Ridvan
    Ozkocaman, Vildan
    Ozkalemkas, Fahir
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [26] The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine
    Takahiro Kamiya
    Tomonori Nakazato
    Medical Oncology, 2019, 36
  • [27] Novel Prognostic Models for Myelodysplastic Syndromes
    Shreve, Jacob
    Nazha, Aziz
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 34 (02) : 369 - +
  • [28] Prognostic factors associated with progression of myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) in patients (pts) treated with decitabine.
    Fullmer, A.
    Borthakur, G.
    Kadia, T. M.
    Garcia-Manero, G.
    Jabbour, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine
    Kamiya, Takahiro
    Nakazato, Tomonori
    MEDICAL ONCOLOGY, 2019, 36 (03)
  • [30] CYTOGENETIC STUDIES IN 69 PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    WEH, HJ
    CALAVREZOS, A
    SEEGER, D
    KUSE, R
    HOSSFELD, DK
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1987, 38 (02) : 166 - 172
12345